Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention.

ABSTRACT:

Importance

Recently, 12 randomized clinical trials (RCTs) have demonstrated the efficacy of novel therapies for mainly secondary prevention of atherosclerotic cardiovascular disease. However, given the potential overlapping eligibility of the RCTs, along with the cost of the new therapies, there are uncertainty and questions about implementing these RCT findings in real-world clinical practice.

Objective

To determine the eligibility and preventive potential for these new preventive therapies in a contemporary population.

Design, setting, and participants

This population-based contemporary cohort study included 6292 patients with known ischemic heart disease (IHD) and 2277 with a previous myocardial infarction (MI) enrolled between November 2003 and February 2015. Anal

SUBMITTER: Mortensen MB 

PROVIDER: S-EPMC6990962 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature